Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force |
| |
| Authors: | Dirk?Dressler mailto:dressler.dirk@mh-hannover.de" title=" dressler.dirk@mh-hannover.de" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Roongroj?Bhidayasiri,Saeed?Bohlega,Abderrahmane?Chahidi,Tae?Mo?Chung,Markus?Ebke,L.?Jorge?Jacinto,Ryuji?Kaji,Serdar?Ko?er,Petr?Kanovsky,Federico?Micheli,Olga?Orlova,Sebastian?Paus,Zvezdan?Pirtosek,Maja?Relja,Raymond?L.?Rosales,José?Alberto?Sagástegui-Rodríguez,Paul?W.?Schoenle,Gholam?Ali?Shahidi,Sofia?Timerbaeva,Uwe?Walter,Fereshte?Adib?Saberi |
| |
| Affiliation: | 1.Movement Disorders Section, Department of Neurology,Hannover Medical School,Hannover,Germany;2.Chulalongkorn Centre for Excellence on Parkinson’s Disease and Related Disorders,King Chulalongkorn Memorial Hospital,Bangkok,Thailand;3.Department of Neurology,King Faisal Specialist Hospital,Riyadh,Kingdom of Saudi Arabia;4.Basic and Clinical Neurosciences Research Laboratory,University Medical School of Marrakech,Marrakech,Morocco;5.University of Sao Paulo,Sao Paulo,Brazil;6.Department of Neurology, Dr. Becker Rhein-Sieg-Klinik,Nümbrecht,Germany;7.Department of Adult Neuro-Rehabilitation, Adult Botulinum Toxin Clinics,Centro de Medicina de Reabilita??o de Alcoit?o,Alcabideche,Portugal;8.Department of Neurology,University of Tokushima,Tokushima,Japan;9.Centre de Rééducation et Medicine Physique,H?pital du Jura,Porrentruy,Switzerland;10.Department of Neurology,Palacky University,Olomouc,Czech Republic;11.Department of Neurology,Hospital de Clínicas José de San Martín, University of Buenos Aires,Buenos Aires,Argentina;12.Clinic ‘Cecil Plus’,Moscow,Russia;13.Department of Neurology,Bonn University,Bonn,Germany;14.Department of Neurology,Ljubljana University Medical Centre,Ljubljana,Slovenia;15.Department of Neurology,University of Zagreb,Zagreb,Croatia;16.Department of Neurology and Psychiatry,University of Santo Tomas Hospital,Manila,Philippines;17.Department of Neurology,Universidad de Monterrey,Monterrey,Mexico;18.Department of Neurology,Maternus-Klinik für Rehabilitation,Bad Oeynhausen,Germany;19.Department of Neurology, Movement Disorders Clinic,Rasoul-e Akram Hospital, Iran University of Medical Sciences,Tehran,Iran;20.Scientific Research Institute of Neurology,Moscow,Russia;21.Department of Neurology,Rostock University,Rostock,Germany;22.IAB-Interdisciplinary Working Group for Movement Disorders,Hamburg,Germany |
| |
| Abstract: | ![]()
Botulinum toxin (BT) therapy is an established treatment of spasticity due to stroke. For multiple sclerosis (MS) spasticity this is not the case. IAB-Interdisciplinary Working Group for Movement Disorders formed a task force to explore the use of BT therapy for treatment of MS spasticity. A formalised PubMed literature search produced 55 publications (3 randomised controlled trials, 3 interventional studies, 11 observational studies, 2 case studies, 35 reviews, 1 guideline) all unanimously favouring the use of BT therapy for MS spasticity. There is no reason to believe that BT should be less effective and safe in MS spasticity than it is in stroke spasticity. Recommendations include an update of the current prevalence of MS spasticity and its clinical features according to classifications used in movement disorders. Immunological data on MS patients already treated should be analysed with respect to frequencies of MS relapses and BT antibody formation. Registration authorities should expand registration of BT therapy for spasticity regardless of its aetiology. MS specialists should consider BT therapy for symptomatic treatment of spasticity. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
